Conatus Pharmaceuticals, a San Diego-based privately held biopharmaceutical company focused on fibrotic disease and oncology, has appointed Mark F. Morris as head of biostatistics.
In this newly created position, Morris will oversee the statistical design of the company's human clinical trials. During the past few months, he has been a consulting statistician to the pharmaceutical industry. Prior to that, Morris had a lengthy career at Pfizer in global R&D in England. He held various positions of increasing responsibility at Pfizer, most recently as director of pulmonary vascular disease where he led a team of statisticians supporting a U.S. regulatory marketing submission. Morris also worked closely with U.S., U.K. and European regulatory agencies, external medical communities and academic institutions.